Traveller vaccination hepatitis E: Difference between revisions
Usama Talib (talk | contribs) No edit summary |
Usama Talib (talk | contribs) No edit summary |
||
| Line 7: | Line 7: | ||
Hepatitis E virus (HEV). It has four known genotypes that infect mammalian hosts (genotypes 1, 2, 3 and 4). | Hepatitis E virus (HEV). It has four known genotypes that infect mammalian hosts (genotypes 1, 2, 3 and 4). | ||
==Transmission== | ==Transmission== | ||
The virus is usually acquired through contaminated drinking-water. Direct faecal–oral transmission from person to person is also possible. There is no insect vector. Various domestic animals, including pigs, may be reservoirs of HEV. | |||
==Nature of the disease== | ==Nature of the disease== | ||
The clinical features and course of the disease are generally similar to those of hepatitis A (see above). However, during the third trimester of pregnancy HEV infection is more serious and is associated with case–fatality rates reaching 20% or higher. In addition to pregnant women, those with pre-existing liver disease and immunosuppressed persons are at greater risk for severe disease following HEV infection. | |||
==Geographical distribution== | ==Geographical distribution== | ||
HEV is a leading cause of acute viral hepatitis in developing countries. Each year HEV genotypes 1 and 2 may account for about 20.1 million HEV infections, 3.4 million symptomatic cases, 70 000 deaths and 3 000 stillbirths. | |||
==Risk for travellers== | ==Risk for travellers== | ||
Travellers to developing countries may be at risk when exposed to poor conditions of sanitation and drinking-water control. | |||
==Vaccine== | ==Vaccine== | ||
* A vaccine against HEV has recently been developed and licensed in China. The vaccine contains a recombinant viral capsid protein corresponding to genotype 1 of HEV, but is likely to protect against all four genotypes. Three doses of the vaccine are given intramuscularly at 0, 1 and 6 months. So far, this vaccine has shown a favourable safety profile as well as excellent immunogenicity and clinical efficacy when used in healthy individuals aged 16-65 years. | |||
* The duration of protection is at least two years. Because of a lack of sufficient information on safety, immunogenicity and efficacy in important target groups such as children under 16 years of age, pregnant women and people with chronic hepatic disorders, WHO does not currently recommend this vaccine for routine use in national programmes of endemic countries. However, vaccination against HEV may be considered in special situations where the risk of contracting HEV is particularly high. For example, WHO recognizes the high risk of HEV infection for travellers, health-care and humanitarian relief workers deployed or travelling to areas where there is an ongoing outbreak of hepatitis E. In such circumstances, each person should be evaluated individually for risks and benefits of vaccination against HEV. | |||
== Precautions == | |||
Travellers should follow the general recommendations for avoiding potentially contaminated food and drinking-water (Chapter 3). | |||
==Summary of vaccine data== | ==Summary of vaccine data== | ||
Revision as of 16:07, 20 April 2017
Template:Traveller vaccination hepatitis E Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]
Overview
Disease cause
Hepatitis E virus (HEV). It has four known genotypes that infect mammalian hosts (genotypes 1, 2, 3 and 4).
Transmission
The virus is usually acquired through contaminated drinking-water. Direct faecal–oral transmission from person to person is also possible. There is no insect vector. Various domestic animals, including pigs, may be reservoirs of HEV.
Nature of the disease
The clinical features and course of the disease are generally similar to those of hepatitis A (see above). However, during the third trimester of pregnancy HEV infection is more serious and is associated with case–fatality rates reaching 20% or higher. In addition to pregnant women, those with pre-existing liver disease and immunosuppressed persons are at greater risk for severe disease following HEV infection.
Geographical distribution
HEV is a leading cause of acute viral hepatitis in developing countries. Each year HEV genotypes 1 and 2 may account for about 20.1 million HEV infections, 3.4 million symptomatic cases, 70 000 deaths and 3 000 stillbirths.
Risk for travellers
Travellers to developing countries may be at risk when exposed to poor conditions of sanitation and drinking-water control.
Vaccine
- A vaccine against HEV has recently been developed and licensed in China. The vaccine contains a recombinant viral capsid protein corresponding to genotype 1 of HEV, but is likely to protect against all four genotypes. Three doses of the vaccine are given intramuscularly at 0, 1 and 6 months. So far, this vaccine has shown a favourable safety profile as well as excellent immunogenicity and clinical efficacy when used in healthy individuals aged 16-65 years.
- The duration of protection is at least two years. Because of a lack of sufficient information on safety, immunogenicity and efficacy in important target groups such as children under 16 years of age, pregnant women and people with chronic hepatic disorders, WHO does not currently recommend this vaccine for routine use in national programmes of endemic countries. However, vaccination against HEV may be considered in special situations where the risk of contracting HEV is particularly high. For example, WHO recognizes the high risk of HEV infection for travellers, health-care and humanitarian relief workers deployed or travelling to areas where there is an ongoing outbreak of hepatitis E. In such circumstances, each person should be evaluated individually for risks and benefits of vaccination against HEV.
Precautions
Travellers should follow the general recommendations for avoiding potentially contaminated food and drinking-water (Chapter 3).